UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 88

Sortiert nach

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD

Biology of blood and marrow transplantation, 2016-03, Vol.22 (3), p.462-469

2016

Link zum Volltext

Verfügbarkeit prüfen

AL Amyloidosis — Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells

Blood, 2018-11, Vol.132 (Supplement 1), p.187-187

2018

Link zum Volltext

Verfügbarkeit prüfen

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Blood, 2017-08, Vol.130 (5), p.632-642

2017

Link zum Volltext

Verfügbarkeit prüfen

Analyse der proliferierenden und ruhenden Fraktion von malignen B-Zellen bei der chronischen lymphatischen Leukamie

Bochtler, Tilmann

2003

Link zum Volltext

Verfügbarkeit prüfen

ATM and ATR Are Not Required for DNA Damage-Dependent Accumulation of Chk1 at the Centrosome

Blood, 2005-11, Vol.106 (11), p.4288-4288

2005

Link zum Volltext

Verfügbarkeit prüfen

Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience

European journal of haematology, 2014-08, Vol.93 (2), p.112-117

2014

Link zum Volltext

Verfügbarkeit prüfen

Cancer of unknown primary (CUP) – lokal begrenzt, oligometastatisch und im Kopf-Hals-Bereich

Die Radiologie, 2023-05, Vol.63 (5), p.358-365

2023

Link zum Volltext

Verfügbarkeit prüfen

Cancer of unknown primary (CUP)-single-site, oligometastatic, and in the head and neck region

Radiologie (Heidelberg, Germany), 2023-05, Vol.63 (5), p.358-365

2023

Link zum Volltext

Verfügbarkeit prüfen

Cancer of unknown primary“ – histologische und molekularpathologische Grundlagen in der Diagnostik

Die Onkologie, 2024-03, Vol.30 (3), p.188-195

2024

Link zum Volltext

Verfügbarkeit prüfen

Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice

Cancers, 2022-06, Vol.14 (12), p.2905

2022

Link zum Volltext

Verfügbarkeit prüfen

Cancer of unknown primary-The new ESMO guidelines

Radiologie (Heidelberg, Germany), 2023-05, Vol.63 (5), p.329-335

2023

Link zum Volltext

Verfügbarkeit prüfen

A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

The oncologist (Dayton, Ohio), 2021-05, Vol.26 (5), p.e769-e779

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis

Blood, 2015-12, Vol.126 (23), p.1790-1790

2015

Link zum Volltext

Verfügbarkeit prüfen

Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3898-3905

2013

Link zum Volltext

Verfügbarkeit prüfen

Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome

International journal of cancer, 2019-12, Vol.145 (11), p.2963-2973

2019

Link zum Volltext

Verfügbarkeit prüfen

Correspondence (reply): In Reply

Deutsches Ärzteblatt international, 2019-04, Vol.116 (14), p.251-251

Bochtler, Tilmann

2019

Link zum Volltext

Verfügbarkeit prüfen

CUP-Syndrom – die neue ESMO-Leitlinie

Die Radiologie, 2023-05, Vol.63 (5), p.329-335

2023

Link zum Volltext

Verfügbarkeit prüfen

CUP-Syndrom – die neue ESMO-Leitlinie

Best practice onkologie, 2023-06, Vol.18 (6), p.234-241

2023

Link zum Volltext

Verfügbarkeit prüfen

Das CUP-Syndrom - Stand 2020

InFo Hämatologie + Onkologie, 2020-04, Vol.23 (4), p.36-47

2020

Link zum Volltext

Verfügbarkeit prüfen

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma

Blood advances, 2018-10, Vol.2 (20), p.2607-2618

2018

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis and management of metastatic neoplasms with unknown primary

Seminars in diagnostic pathology, 2018-05, Vol.35 (3), p.199-206

2018

Link zum Volltext

Verfügbarkeit prüfen

DNA Damage-Induced Accumulation of Centrosomal Chk1 Contributes to its Checkpoint Function

Cell cycle (Georgetown, Tex.), 2007-10, Vol.6 (20), p.2541-2548

2007

Link zum Volltext

Verfügbarkeit prüfen

Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?

Frontiers in oncology, 2019-05, Vol.9, p.402-402

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Toxicity of Dose-Reduced Bortezomib/Dexamethasone Chemotherapy In Patients with High Risk Cardiac Light Chain Amyloidosis (Mayo Clinic stage III)

Blood, 2010-11, Vol.116 (21), p.1960-1960

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(82)

Publikationsform

Sprache

Englisch
(76)
Deutsch
(12)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD

AL Amyloidosis — Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Analyse der proliferierenden und ruhenden Fraktion von malignen B-Zellen bei der chronischen lymphatischen Leukamie

ATM and ATR Are Not Required for DNA Damage-Dependent Accumulation of Chk1 at the Centrosome

Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience

Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

Cancer of unknown primary (CUP) – lokal begrenzt, oligometastatisch und im Kopf-Hals-Bereich

Cancer of unknown primary (CUP)-single-site, oligometastatic, and in the head and neck region

Cancer of unknown primary“ – histologische und molekularpathologische Grundlagen in der Diagnostik

Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice

Cancer of unknown primary-The new ESMO guidelines

A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis

Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia

Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome

Correspondence (reply): In Reply

CUP-Syndrom – die neue ESMO-Leitlinie

CUP-Syndrom – die neue ESMO-Leitlinie

Das CUP-Syndrom - Stand 2020

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma

Diagnosis and management of metastatic neoplasms with unknown primary

DNA Damage-Induced Accumulation of Centrosomal Chk1 Contributes to its Checkpoint Function

Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?

Efficacy and Toxicity of Dose-Reduced Bortezomib/Dexamethasone Chemotherapy In Patients with High Risk Cardiac Light Chain Amyloidosis (Mayo Clinic stage III)

Suchergebnisse filtern